Dr. Claire Harrison on the Benefits of Ruxolitinib in Advanced Myelofibrosis
Claire Harrison, MD, discusses ruxolitinib continuing to show a benefit for patients with advanced myelofibrosis over the course of a 5 year study.
Claire Harrison, MD, professor of hematology, Guy’s and St. Thomas’ NHS Foundation Trust, discusses ruxolitinib continuing to show a benefit for patients with advanced myelofibrosis over the course of a 5 year study.
Ruxolitinib was approved by the FDA in 2011 and improved and maintained reduction and overall survival in the the COMFORT-II study. In earlier findings that led to the therapy’s approval, published in 2012, ruxolitinib significantly decreased spleen size in 28% of patients, but no decrease was seen in patients in the control arm, who were taking best available therapy (BAT).
Harrison says the drug has significantly improved patients' lives and adds that there will be a study of ruxolitinib and its effects on early plhase myelofibrosis in the future.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
